• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Alcami

    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Alcami

    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Can mRNA Facilities Really be Flexible?

    Four key questions to accommodate growth and expansion.

    Can mRNA Facilities Really be Flexible?
    Related CONTENT
    • AmbioPharm, Inc.
    • Legacy Pharma Solutions
    • Vio Chemicals
    • W. R. Grace FCMS
    • WuXi AppTec
    Jeff Heil, PE , Novel Therapy SME, DPS Group Global07.08.21
    The pharmaceutical industry is increasingly embracing modular facility design when creating spaces for manufacturing treatments, vaccines and other pharma products. Such agile or flexible facilities often promise the capability of modifying design as easily as swapping out building blocks, creating an easier and more cost-conscious way to expand capabilities as the business grows.

    Despite these advantages, there are many considerations to take into account when incorporating flexible facility design in a pharmaceutical development and manufacturing strategy. Even in flexible facilities, some aspects of design and construction are essentially fixed, such as constraints regarding HVAC and electrical systems – and, consequently, the physical dimensions of the facilities themselves.

    This is particularly true for organizations introducing mRNA production in their pharmaceutical development strategy. While this article will provide general considerations in flexible facility design, it’s important to keep in mind how certain procedures, such as mRNA production, can limit how flexible your flexible facility actually can be.

    Some mRNA design considerations
    Depending on the scale of the operation (that is, pre-clinical versus commercial manufacturing), a facility may have vastly different utility, equipment and spatial requirements. Typically, separate suites are provided for production of buffer, plasmids, mRNA, Lipid Nanoparticle (LNP), and filling. These are all commonly ISO Grade C clean room environments.
     
    In mRNA production, multiple filtration/concentration and chromatography steps typically are required, and each step may require a unique equipment set-up. The full process may have five or more chromatography/Tangential Flow Filtration (TFF) steps, and may require a minimum amount for floor space to facilitate these unit operations. Additionally, reverse phase chromatography is common for protein purification, and often requires solvent storage and usage, which adds to electrical classification and building code concerns.
     
    What’s more, mRNA product intermediates require analytical/quality testing that takes time to complete and the mRNA molecules are often unstable at these critical testing points in the process. This product instability may call for additional equipment requirements in the facility, such as controlled rate freezers and storage space in ultra-low temperature freezers. Design of freezer farms in facilities requires careful consideration due to the HVAC loads they impart in their surroundings, and energy consumption from both the freezers and HVAC equipment needed to reject their generated heat.
     
    Lipid nano particle production also requires the use of 100% ethanol. Use of such a flammable substance challenges the room hazard and electrical classifications – especially with other typically non-rated equipment used downstream of the lipid production. The greater the process scale, the greater the challenge in coordinating around these and other design requirements.
     
    Facility design in the COVID era: Planning questions
    Despite the need for thorough facility planning, the reality of drug research and development during the pandemic has emphasized the need for faster facility design. Operation Warp Speed  in particular ushered in an environment that is more conducive to a “design-build” partnership in the industry. This is true depending on whether the risk versus reward yields a favorable outcome, because design-build does require the mitigation of certain risks.
     
    Traditionally, a facility is completely designed before construction is undertaken. In a design-build partnership as mentioned above, project design may, for example, be 60% complete when construction partners are brought in. The design work is continued more or less in parallel with the construction. As the architect is designing the balance of the facility, the construction contractors are already on site, considering their plan for construction, providing input on what has already been done and recommending placement of required equipment. This can substantially reduce the time (and, potentially, the cost) of building a facility over the traditional method, but it carries risk if late-stage changes in the design are requested.
     
    As you embark on your flexible facility design, there are four general questions to keep in mind to ensure a successful design outcome:
     
    Are you thinking far enough ahead?
    Architects and engineers need to understand what your possible plans for expansion may be, and how the facility may be have to be built out. Have you considered how your facility can be expanded?
     
    Understand the limitations of your space. Is the available footprint sufficient for expansion? It is generally preferable to expand within the existing footprint, and that raises its own issues. There may be some workarounds available. For example, do you have an atrium area that you could convert relatively quickly into more manufacturing space if needed? If so, does that space have the ceiling height required to accommodate all of the ductwork necessary for the expanded facility? (A minimum ceiling height in a suite should be not less than nine feet, and should also allow for the possibility of bump-up high ceilings areas for larger equipment.)
     
    This is a particularly important consideration even during site selection of an existing facility. There is not a lot of greenfield design in the pharmaceutical industry at the moment. Many facilities are retrofitted into existing, “brownfield” buildings. It’s essential to understand how to accommodate your facility in a footprint that may not have been purpose built for your particular needs.
     
    What are your actual processing/manufacturing requirements?
    Your particular manufacturing planshave requirements that must be addressed fully in the design stage. For example, if you are using mRNA, and you’ll be doing plasma manufacturing in the same location, these are typically treated as two separate product facilities. You’ll need individual gowning spaces, and airlocks to support both the plasmid DNA side of the facility and the actual mRNA manufacturing component. All of those considerations factor into the square footage footprint required for that facility.
     
    How are you accommodating materials storage?
    We can’t overstate the importance of adequately considering material storage in facility design. Feed stock, seeding cells, drug substance, and drug products may all have different storage requirements – particularly with mRNA facilities, but also in general. Material storage requirements can typically include 2-8 degree Centigrade refrigerators for thawing material, -20 degree Centigrade freezers for feed stock such as plasmid storage, and cryogenic storage for cell banks and for mRNA products. Your plan must address these requirements. You will also need to assess your material storage against the allowable limits for hazard areas.
     
    What is your HVAC/Electrical power and back-up strategy?
    We’ve touched on this briefly above, but it bears repeating: HVAC is not particularly flexible. Rather, aspects such as the size of air handlers and placement of duct work are vital to the successful design of the facility. Your HVAC infrastructure must not only be sufficient for the facility as you plan to use it today; it also must support plans five or more years down the road. The same is true for running electrical power through the facility. Some aspects of design and construction cannot be easily changed, even in a “flexible” facility.
     
    “Flexible” can be a slightly misleading term in setting expectations and design philosophies. Giving the facility the agility to pivot; be repurposed or expanded without significant, unnecessary infrastructure changes or interruptions to ongoing operations is the objective. Flexible or agile facilities can be an efficient and cost-effective way to create a design that will accommodate growth and expansion. Flexibility cannot necessarily extend to every design element. By understanding your needs not only now but in the future; as well as the limitations imposed on design by the work being planned; you will create a plan that gives you the agility to move quickly and easily with your program and product development.


    Jeff Heil, PE is the Process Engineering Discipline Manager for DPS Group with subject matter expertise in mRNA, oligonucleotide and vaccine development. Jeff  brings over 15 years of process engineering and technical project management expertise in a diverse port­folio of engineering applications with unique insight into the design challenges associated with the processing of compressible, multi-phase, and hazardous materials in brownfield and greenfield applications. Jeff is also experienced in the design and validation of process safety systems, providing independent technical assurance of engineering work, and working directly with clients to solve complex engineering problems in a variety of applications. He specializes in leading the execution of process projects with a background in hazardous materials, industrial processes, and small molecule chemistry. He can be reached at Jeffrey.Heil@dpsgroupglobal.com
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    AmbioPharm, Inc. AmbioPharm, Inc.
    Legacy Pharma Solutions Legacy Pharma Solutions
    Vio Chemicals Vio Chemicals
    W. R. Grace FCMS W. R. Grace FCMS
    WuXi AppTec WuXi AppTec
    ViscoTec America Inc. ViscoTec America Inc.
    Thomas Scientific LLC Thomas Scientific LLC
    PCI Pharma Services PCI Pharma Services
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Boyds Opens US Office in PA Boyds Opens US Office in PA

    Related Content

    • AmbioPharm, Inc.

      ...
      Denise Karounos, Sr Marketing Manager 04.05.22

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Vio Chemicals

      ...
      Ioanna Kazantzidou, Marketing Communications Officer 12.07.21


    • W. R. Grace FCMS

      W. R. Grace FCMS

      ...
      Stella Ip, Director Marketing Health and Life Sciences 11.23.21

    • WuXi AppTec

      ...
      Daja Herald, Marketing Director 11.22.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      • Insmed Appoints Drayton Wise as Chief Commercial Officer
      • Clinigen Expands U.S. Site Capacity
      • Corealis CDMO Completes Deal with ArchiMed
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Pediatric Medical Device Competition Reveals Five Finalists
      Medical Device Packaging Market to Reach $34B by 2027
      Penumbra Secures CE Mark for its Advanced Mechanical Thrombectomy Tech
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      TikToker Abbie Herbert, Founder of Personal Care Brand Pavot, Launches Body Water, Razor Burn Treatment Pads With Beaubble Partnership
      E.l.f. Cosmetics Introduces ‘Big Mood Pride Mascara’ Ahead of Pride Month
      Ink World

      Latest Breaking News From Ink World

      Epson Introduces Two New SurePress Digital Label Presses
      Flint Group Flexible Packaging Europe Implements Further Price Increase
      Nazdar Launches 205 Series Inks for Roland TrueVIS SG2 and VG2 Series Printers
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      InnovationLab Acquires Flexible Printed Battery Technology from Evonik
      Canatu Receives IATF 16949:2016 Certification
      Applied Materials Announces 2Q 2022 Results

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login